Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Total Liabilities
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has total liabilities worth CN¥842.81 Million CNY (≈ $123.33 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 688578 net asset momentum to track the company's year-over-year net asset growth rate.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Total Liabilities Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See 688578 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Autoliv Inc.
F:LIV
|
Germany | €5.82 Billion |
|
Yunnan Chihong Zinc&Germanium Co Ltd
SHG:600497
|
China | CN¥7.60 Billion |
|
Powell Industries Inc
NASDAQ:POWL
|
USA | $470.97 Million |
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
China | CN¥6.67 Billion |
|
NIBE Industrier AB (publ)
ST:NIBE-B
|
Sweden | Skr34.77 Billion |
|
Yes Bank Limited
NSE:YESBANK
|
India | Rs4.19 Trillion |
|
SSAB AB (publ)
ST:SSAB-B
|
Sweden | Skr38.39 Billion |
|
MITSU.CH.GRP ADR/5
F:M3C0
|
Germany | €3.28 Trillion |
Liability Composition Analysis (2017–2025)
This chart breaks down Shanghai Allist Pharmaceuticals Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Allist Pharmaceuticals Co. Ltd. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Allist Pharmaceuticals Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below shows the annual total liabilities of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-6.50 Billion ≈ $-950.98 Million |
-1126.15% |
| 2024-12-31 | CN¥633.32 Million ≈ $92.67 Million |
+60.65% |
| 2023-12-31 | CN¥394.22 Million ≈ $57.69 Million |
+54.52% |
| 2022-12-31 | CN¥255.12 Million ≈ $37.33 Million |
+62.50% |
| 2021-12-31 | CN¥156.99 Million ≈ $22.97 Million |
+44.02% |
| 2020-12-31 | CN¥109.01 Million ≈ $15.95 Million |
-24.31% |
| 2019-12-31 | CN¥144.02 Million ≈ $21.07 Million |
-52.62% |
| 2018-12-31 | CN¥303.96 Million ≈ $44.48 Million |
+138.64% |
| 2017-12-31 | CN¥127.37 Million ≈ $18.64 Million |
-- |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more